ARTICLE | Company News

Quigley neurology, inflammation news

December 14, 2009 8:00 AM UTC

Quigley will reduce spending in its Quigley Pharma Inc. subsidiary to focus on its OTC programs. The company said it may make "further reasonable investment" in QR333, a topical formulation of quercetin, ascorbyl palmitate and vitamin D3 which missed the primary endpoints in a Phase IIb trial for diabetic peripheral neuropathy (DPN); QR440, a botanical broad-spectrum anti-inflammatory compound in preclinical testing to treat inflammation and joint pain; and veterinary compound QR448. Also, Quigley Pharma EVP and COO Richard Rosenblum departed the company, but remains as a consultant. ...